论文部分内容阅读
目的分析甲状腺良恶性结节中34βE12、Galectin-3及HBME-1的表达状况,并探讨其在鉴别甲状腺乳头状癌(papillary thyroid carcinoma,PTC)与甲状腺良性结节中的临床价值。方法采用免疫组化En Vision TM两步法检测352例患者中34βE12、Galectin-3及HBME-1的表达水平,分析这3个蛋白标记物与PTC临床病理特征的相关性,利用ROC曲线评估其鉴别诊断价值。结果 34βE12、Galectin-3及HBME-1在PTC病灶中的阳性率均显著高于甲状腺良性结节中的表达水平,且这3个蛋白标记物在PTC不同性别、年龄、病灶数目、肿瘤大小、包膜是否突破、有无淋巴结转移以及TNM分期中的表达差异均无统计学意义(P均>0.05)。34βE12、Galectin-3及HBME-1对鉴别PTC与甲状腺良性疾病中的ROC曲线下面积(AUC)分别为0.936、0.915、0.898,灵敏度分别为94.3%、95.5%、91.1%,特异度分别为81.1%、71.7%、83.0%,准确度分别为90.3%、88.4%、88.6%。结论 34βE12、Galectin-3及HBME-1在甲状腺良恶性结节中的表达存在统计学差异,并且与PTC的临床病理特征无关,对鉴别甲状腺良恶性结节的性质具有重要的临床辅助价值。
Objective To analyze the expression of 34βE12, Galectin-3 and HBME-1 in benign and malignant thyroid nodules and to explore their clinical value in differentiating papillary thyroid carcinoma (PTC) from benign thyroid nodules. Methods The expression levels of 34βE12, Galectin-3 and HBME-1 in 352 patients were detected by immunohistochemical En Vision TM two-step method. The correlation between the three protein markers and clinicopathological features of PTC was analyzed. The ROC curve Differential diagnosis value. Results The positive rates of 34βE12, Galectin-3 and HBME-1 in PTC lesions were significantly higher than those in benign thyroid nodules, and the three protein markers were significantly different in different gender, age, number of lesions, tumor size, There was no significant difference in the level of capsule, lymph node metastasis and TNM staging (all P> 0.05). The areas under the ROC curve (AUC) of 34βE12, Galectin-3 and HBME-1 in differentiating PTC from thyroid benign disease were 0.936, 0.915 and 0.898, respectively, with sensitivities of 94.3%, 95.5% and 91.1%, respectively, and their specificity were 81.1 %, 71.7% and 83.0% respectively, with accuracy of 90.3%, 88.4% and 88.6% respectively. Conclusions The expression of 34βE12, Galectin-3 and HBME-1 in benign and malignant thyroid nodules is statistically different and has nothing to do with the clinicopathological features of PTC. It has important clinical value in differentiating benign and malignant thyroid nodules.